Literature DB >> 10771294

Naloxone potentiates anxiolytic-like actions of diazepam, pentobarbital and meprobamate but not those of Ro19-8022 in the rat.

C Belzung1, S Barreau, A Agmo.   

Abstract

The elevated plus-maze test was used to determine if the opiate antagonist naloxone could potentiate the anxiolytic-like effects of the benzodiazepine diazepam, the barbiturate pentobarbital, the propanediol carbamate meprobamate and the partial benzodiazepine receptor agonist [R]-1-[(10-chloro-4-oxo-3-phenyl-4H-benzo[a]quinolizin-1-yl) carbonyl]-2-pyrrolidine-methanol (Ro19-8022) in the rat. A subeffective dose of each of these compounds was combined with naloxone, 10 mg/kg. Naloxone had no effect by itself, but potentiated all drugs except Ro19-8022. The proportion of entries on the open arm increased while the total number of arms entries was not modified. These results coincide with and extend data previously obtained in the mouse. One possible explanation for naloxone's effect could be that it blocks opioid inhibition of GABAergic (gamma-aminobutyric acid) neurons thereby enhancing the effects of benzodiazepines. Another possibility is that naloxone blocks opioid effects on adenosinergic systems.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10771294     DOI: 10.1016/s0014-2999(00)00151-5

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes.

Authors:  R J Rodgers; R Augar; N Berryman; C J Hansom; M L O'Mahony; R M Palmer; A Stevens; A J Tallett
Journal:  Psychopharmacology (Berl)       Date:  2006-06-27       Impact factor: 4.530

2.  The role of delta opioid receptors in the anxiolytic actions of benzodiazepines.

Authors:  Stefany D Primeaux; Steven P Wilson; Alexander J McDonald; Franco Mascagni; Marlene A Wilson
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.